The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

United Therapeutics Corp

Nasdaq: UTHR
Last

(U.S.) $149.96

Today's change-3.79 -2.47%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

United Therapeutics Corp

Nasdaq: UTHR
Last

(U.S.) $149.96

Today's change-3.79 -2.47%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

United Therapeutics Corp down (U.S.)$3.79

United Therapeutics Corp closed sharply lower Thursday, dropping (U.S.)$3.79 or 2.47% to (U.S.)$149.96. Shares have lost 6.42% over the last five days, but have gained 15.81% over the last year to date. This security has outperformed the S&P 500 by 34.49% during the last year.

Key company metrics

  • Open(U.S.) $154.77
  • Previous close(U.S.) $153.75
  • High(U.S.) $159.99
  • Low(U.S.) $149.73
  • Bid / Ask-- / --
  • YTD % change+15.81%
  • Volume425,132
  • Average volume (10-day)671,131
  • Average volume (1-month)553,582
  • Average volume (3-month)581,579
  • 52-week range(U.S.) $110.12 to (U.S.) $190.29
  • Beta1.48
  • Trailing P/E47.05×
  • P/E 1 year forward21.50×
  • Forward PEG1.14×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.19
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.83%

Based on its net profit margin of 12.83%, United Therapeutics Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.38%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue347328346330
Total other revenue--------
Total revenue347328346330
Gross profit331307331289
Total cost of revenue16211641
Total operating expense175342168362
Selling / general / administrative11021181203
Research & development4911071119
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income172-15179-32
Interest income (expense), net non-operating-1-2-4-5
Gain (loss) on sale of assets--------
Other--------
Income before tax168-17175-36
Income after tax99-17116-25
Income tax, total69059-11
Net income99-17116-25
Total adjustments to net income--------
Net income before extra. items99-17116-25
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items99-17116-25
Inc. avail. to common incl. extra. items99-17116-25
Diluted net income99-17116-25
Dilution adjustment--------
Diluted weighted average shares52475447
Diluted EPS excluding extraordinary itemsvalue per share1.91-0.362.17-0.53
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share1.91-0.362.17-0.53